Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ºñ´¢±â°ú ¿µ¿ª¿¡¼­ÀÇ Vibramycin Precon PT-122MÀÇ È¿°ú Effect of Vibramycin Precon PT-122M in urogenital infections

´ëÇѾฮÇÐÀâÁö 1977³â 13±Ç 1È£ p.23 ~ 27
ÀÓÁ¤±Ô, ½Å»ó±¸, ì°Ïíûà, Àå´ë¼ö,
¼Ò¼Ó »ó¼¼Á¤º¸
ÀÓÁ¤±Ô (  ) 
¼­¿ï´ëÇб³ Àǰú´ëÇÐ ¾à¸®Çб³½Ç

½Å»ó±¸ (  ) 
¼­¿ï´ëÇб³ Àǰú´ëÇÐ ¾à¸®Çб³½Ç
ì°Ïíûà (  ) 
¼­¿ï´ëÇб³ Àǰú´ëÇÐ ¾à¸®Çб³½Ç
Àå´ë¼ö (  ) 
Áߺñ½Ã¸³º´¿ø ºñ´¢±â°ú

Abstract


To investigate the efficacy, tolerance of Vibramycin Precon PT-122 M and to determine the nature, incidence and severity of side effects of this formulation, 19 patients with urogenital infections were studied.
1. Vibramycin Precon PT-122 M reduced the signs and symptoms of various urogenital infections so as to determine the overall efficacy as good or satisfactory.
2. Intravenous injection of PT-122 M was generally well tolerated in all patients except 2 case of discontinuation because of adverse effect.
3. PT-122 M showed mild to moderate side effects but clinical features ana response to therapy were not influencea by those side effects.

Ű¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KAMS